{
    "nct_id": "NCT00391833",
    "title": "Effect of Panax Ginseng on the Cognitive Performance in Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2006-10-22",
    "description_brief": "We investigate the clinical efficacy of Panax ginseng in Alzheimer's disease (AD).",
    "description_detailed": "Alzheimer's disease (AD) is characterized by a progressive decline of memory and intellectual abilities, interfering activity in daily living, the overall quality of life, and ultimately leads to death. Although pharmacologic treatments are currently approved for treating mild- to moderate AD using acetylcholinesterase inhibitors (ACEI) or memantine, the NMDA antagonist, for the advanced stage of AD, the therapeutic efficacies need to be further improved.\n\nFor millennia, ginseng or its components have been used to treat medical conditions, and the pharmacologic effects have been demonstrated in cardiovascular, endocrine and immune system (Attele et al., 1999). In means of memory and learning, a number of studies suggested that ginseng can attenuate learning deficits of damaged or ageing brains in rodent models (Kennedy et al., 2003; Zhao and McDaniel, 1998; Nitta et al., 1995). In studies with human healthy participants, correspondently, both acute and chronic dosage of ginseng increased the cognitive performance (Kennedy et al., 2001; Kennedy et al., 2003; D'Angelo et al., 1986; Sorensen and Sonne, 1996).\n\nIn this study, we we will investigate the contribution of ginseng treatment in increasing the cognitive improvement of AD patients. In addition, we will test various bio-markers and hematopoietic progenitor cell count in those included patients using their blood samples. Patients with AD as well as memory decline will be included",
    "phase": [
        "PHASE1",
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "cognitive enhancer",
    "drug": [
        "Panax ginseng (herbal extract; active components: ginsenosides, gintonin)"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The intervention is Panax ginseng, a multi-component herbal extract whose active constituents (ginsenosides, gintonin) have been reported to modulate cholinergic function, exert antioxidant/anti-inflammatory and neuroprotective effects, and in some preclinical work influence amyloid/tau-related pathways; however clinical studies and the trial title focus on effects on cognitive performance (MMSE, ADAS-cog), indicating the intended effect is cognitive enhancement rather than a targeted biologic or a single small-molecule disease-modifying therapy. \ue200cite\ue202turn0search1\ue202turn0search5\ue201",
        "Act: Key trial details and web-search findings \u2014 the published clinical study titled \u201cPanax ginseng enhances cognitive performance in Alzheimer disease\u201d reports an open-label randomized trial (ginseng vs control) with 4.5 g/day Panax ginseng for 12 weeks and improvements in MMSE and ADAS-cog during treatment. Longer/open trials with Korean red ginseng also reported cognitive benefit in AD. Systematic reviews note limited and low-quality clinical evidence overall. These sources support that the intervention is being studied for cognitive improvement. \ue200cite\ue202turn0search0\ue202turn0search8\ue202turn0search2\ue201",
        "Reflect: Classification rationale and caveats \u2014 I classify this trial as 'cognitive enhancer' because the intervention (Panax ginseng) and the trial endpoints explicitly target cognitive performance (MMSE, ADAS-cog). Although preclinical and some review articles describe potential effects on AD pathology (amyloid/tau) and cholinergic systems, Panax ginseng in clinical trials has primarily been evaluated for symptomatic cognitive benefit rather than as a defined biologic (e.g., monoclonal antibody) or a single small-molecule disease-targeted therapy. Evidence is limited and not definitive; Cochrane and systematic reviews call for higher-quality randomized, double-blind, placebo-controlled trials. \ue200cite\ue202turn0search5\ue202turn0search3\ue201",
        "Web search results cited (key sources): 1) RCT/open-label trial \u2014 \"Panax ginseng enhances cognitive performance in Alzheimer disease\" (PubMed; trial reporting 4.5 g/day, improvements in MMSE and ADAS-cog). \ue200cite\ue202turn0search0\ue201 2) Long-term Korean red ginseng study showing sustained cognitive improvements (24 weeks and follow-up). \ue200cite\ue202turn0search8\ue201 3) Reviews summarizing ginseng constituents (ginsenosides, gintonin) and mechanisms relevant to cognition and AD pathology. \ue200cite\ue202turn0search1\ue202turn0search5\ue201 4) Systematic review / Cochrane noting limited/low-quality evidence and need for better trials. \ue200cite\ue202turn0search2\ue202turn0search3\ue201"
    ],
    "agent_type": "R) Multi-target",
    "explanation_agent": [
        "Reason: The intervention is Panax ginseng (multi-component herbal extract; active constituents ginsenosides and gintonin) reported to modulate multiple biological processes \u2014 cholinergic neurotransmission, antioxidant and anti-inflammatory pathways, neuroprotection, and in some preclinical reports effects on amyloid/tau pathways. These span several CADRO categories (D, F, G, M and possibly A/B), so the most specific CADRO assignment is R) Multi-target.",
        "Act: Extracted details \u2014 trial drug: Panax ginseng (ginsenosides, gintonin); trial endpoints: cognitive tests (MMSE, ADAS\u2011cog); reported/claimed mechanisms: cholinergic modulation (neurotransmitter receptors), antioxidant/anti-inflammatory actions, neuroprotective effects, and some preclinical influence on amyloid/tau. Because multiple distinct targets/pathways are implicated rather than a single, well-defined molecular target, assign R) Multi-target. Missing/ambiguous info: no single dominant molecular target or confirmed disease\u2011modifying mechanism in the clinical trial reports.",
        "Reflect: Confirmation and caveats \u2014 CADRO lacks a dedicated \u2018symptomatic cognitive enhancer\u2019 bucket; given the multi-modal pharmacology of ginseng and the trial\u2019s symptomatic cognitive focus, R) Multi-target best fits. If one insisted on a single-category mapping based solely on a dominant proposed mechanism (e.g., cholinergic effects), D) Neurotransmitter Receptors could be argued, but that would ignore the other reported mechanisms. If the trial were purely diagnostic/non\u2011therapeutic, the correct CADRO label would be T) Other \u2014 not the case here.",
        "Web-search results (summary of cited sources provided by the user): 1) RCT/open-label study \u201cPanax ginseng enhances cognitive performance in Alzheimer disease\u201d \u2014 used 4.5 g/day for 12 weeks with reported MMSE and ADAS\u2011cog improvements. 2) Longer/open trials with Korean red ginseng reporting sustained cognitive benefit (24 weeks and follow-up). 3) Reviews describing ginsenosides and gintonin and mechanisms relevant to cognition and AD pathology (cholinergic modulation, antioxidant/anti\u2011inflammatory, neuroprotection, possible amyloid/tau effects). 4) Systematic reviews/Cochrane\u2011style assessments noting limited and low\u2011quality clinical evidence and calling for larger, randomized, placebo\u2011controlled trials. These sources support symptomatic cognitive enhancement and multiple biological mechanisms, consistent with the R) Multi-target assignment."
    ]
}